Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives $6.63 Consensus Target Price from Analysts

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) has earned an average rating of “Buy” from the eight brokerages that are covering the company, Marketbeat Ratings reports. Eight investment analysts have rated the stock with a buy recommendation. The average 1 year target price among brokers that have issued a report on the stock in the last year is $6.63.

A number of equities research analysts recently issued reports on the stock. Canaccord Genuity Group upped their price target on shares of Taysha Gene Therapies from $6.00 to $8.00 and gave the company a “buy” rating in a research note on Friday, November 15th. Needham & Company LLC restated a “buy” rating and set a $6.00 target price on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th. JMP Securities reaffirmed a “market outperform” rating and issued a $5.00 price target on shares of Taysha Gene Therapies in a report on Tuesday, November 12th. Cantor Fitzgerald reissued an “overweight” rating and set a $7.00 price objective on shares of Taysha Gene Therapies in a research note on Tuesday, November 12th. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a research note on Thursday, November 14th.

Hedge Funds Weigh In On Taysha Gene Therapies

Hedge funds and other institutional investors have recently modified their holdings of the business. Wellington Management Group LLP acquired a new stake in Taysha Gene Therapies in the 3rd quarter valued at about $931,000. Charles Schwab Investment Management Inc. increased its holdings in shares of Taysha Gene Therapies by 7.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 462,867 shares of the company’s stock valued at $930,000 after purchasing an additional 33,123 shares during the last quarter. Bank of New York Mellon Corp purchased a new position in Taysha Gene Therapies during the second quarter worth approximately $1,018,000. Creative Planning acquired a new position in Taysha Gene Therapies during the third quarter worth $28,000. Finally, SG Americas Securities LLC purchased a new stake in Taysha Gene Therapies in the 3rd quarter valued at $129,000. 77.70% of the stock is owned by hedge funds and other institutional investors.

Taysha Gene Therapies Stock Down 5.9 %

NASDAQ TSHA opened at $1.75 on Thursday. Taysha Gene Therapies has a 52 week low of $1.19 and a 52 week high of $4.32. The company has a quick ratio of 5.51, a current ratio of 5.51 and a debt-to-equity ratio of 0.48. The company has a market capitalization of $358.65 million, a P/E ratio of 2.78 and a beta of 0.79. The stock’s 50-day moving average price is $2.12 and its 200-day moving average price is $2.24.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.